Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837834 | 0.85 | — | — | |
| SCHEMBL3409676 | 0.84 | POLB (0.31) | SIGMAR1POLBSMN1; SMN2 | |
| SCHEMBL8078558 | 0.82 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL3912391 | 0.81 | NPC1 (0.32) | — | |
| Ammonia Solution, Strong SCHEMBL28024639 | 0.80 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL18499722 | 0.79 | GNAO1 (0.34) | SIGMAR1POLBSMN1; SMN2 | |
| SCHEMBL22570088 | 0.77 | CA2 (0.35) | SIGMAR1POLBSMN1; SMN2 | |
| SCHEMBL6627321 | 0.76 | POLB (0.32) | SIGMAR1POLBSMN1; SMN2 | |
| SCHEMBL18993549 | 0.76 | GNAO1 (0.40) | SIGMAR1 | |
| SCHEMBL5707113 | 0.75 | CYP2D6 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3013824-A1 | CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Alzprotect (FR) | 2016-05-04 | — | — | EP | disclosed |
| WO-2015091532-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014207240-A1 | CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | ALZPROTECT (FR) | 2014-12-31 | — | — | WO | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-1345603-A4 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6683093-B2 | ENZYME INHIBITORS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| EP-1345603-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | Merck & Co., Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002058695-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | SIGMAR1 647/4885POLB 1929/4885SMN1; SMN2 1926/4885 |
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MRPL21, F12, MRPS34 | SIGMAR1 1497/4885POLB 1730/4885SMN1; SMN2 2004/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | SIGMAR1 797/4885POLB 2009/4885SMN1; SMN2 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.